Immunocore Holdings plc (NASDAQ: IMCR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.19 | Insider Own | 6.35% | Shs Outstand | 50.83M | Perf Week | -1.84% |
| Market Cap | 1.63B | Forward P/E | - | EPS next Y | -0.60 | Insider Trans | 0.00% | Shs Float | 50.34M | Perf Month | -13.19% |
| Enterprise Value | 1.58B | PEG | - | EPS next Q | -0.16 | Inst Own | 104.07% | Short Float | 15.48% | Perf Quarter | 11.89% |
| Income | -9.27M | P/S | 4.03 | EPS this Y | 66.31% | Inst Trans | - | Short Ratio | 15.03 | Perf Half Y | 6.52% |
| Sales | 403.72M | P/B | 3.89 | EPS next Y | -834.44% | ROA | -0.83% | Short Interest | 7.79M | Perf YTD | -7.81% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -2.35% | 52W High | 40.71 -21.40% | Perf Year | -4.25% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | 13.56% | 52W Low | 27.56 16.11% | Perf 3Y | -39.82% |
| Dividend Est. | - | EV/EBITDA | 97.24 | Sales past 3/5Y | 27.43% 58.28% | Gross Margin | 98.85% | Volatility | 3.79% 3.20% | Perf 5Y | -0.09% |
| Dividend TTM | - | EV/Sales | 3.91 | EPS Y/Y TTM | 81.37% | Oper. Margin | -4.33% | ATR (14) | 1.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.44 | Sales Y/Y TTM | 62.90% | Profit Margin | -2.31% | RSI (14) | 34.80 | Recom | 2.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.47 | EPS Q/Q | 90.00% | SMA20 | -8.80% | Beta | 0.80 | Target Price | 39.00 |
| Payout | 0.00% | Debt/Eq | 1.04 | Sales Q/Q | 18.37% | SMA50 | -7.50% | Rel Volume | 0.93 | Prev Close | 32.30 |
| Employees | 524 | LT Debt/Eq | 1.14 | Earnings | Nov 05 | SMA200 | -1.52% | Avg Volume | 509.11K | Price | 32.00 |
| IPO Date | Feb 05, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -305.32% 5.03% | Net Debt/EBITDA | -3.08 | Volume | 475,903 | Change | -0.93% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Morgan Stanley | Equal Weight | $40 → $43 |
| Aug-03-26 | Reiterated | Mizuho | Neutral | $38 → $35 |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold | |
| Feb-19-26 | Reiterated | Mizuho Securities | Neutral | $37 → $38 |
| Jan-07-26 | Reiterated | UBS | $24 → $55 | |
| Nov-10-25 | Reiterated | Morgan Stanley | Equal Weight | $35 → $36 |
| Oct-31-25 | Initiated | Wells Fargo | Overweight | $60 |
| Mar-07-25 | Reiterated | Morgan Stanley | Equal Weight | $35 |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal Weight | |
| Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 404 | 298 | 248 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 5 | 6 | 6 | — | — | — | — | — | — | |
| Gross Profit | 399 | 291 | 242 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 153 | 121 | 121 | — | — | — | — | — | — | |
| Research and Development | 264 | 204 | 177 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | 1 | — | — | — | — | — | — | |
| Operating Income | -18 | -34 | -56 | — | — | — | — | — | — | |
| Interest Expense | 11 | 12 | 19 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 31 | 32 | 33 | — | — | — | — | — | — | |
| Net Income Before Taxes | 0 | -14 | -42 | — | — | — | — | — | — | |
| Income Taxes | 11 | 12 | -1 | — | — | — | — | — | — | |
| Consolidated Net Income | -9 | -26 | -41 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -9 | -26 | -41 | — | — | — | — | — | — | |
| Net Income | -9 | -26 | -41 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.18 | -0.53 | -1.02 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.18 | -0.53 | -1.02 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.19 | -0.53 | -1.02 | — | — | — | — | — | — | |
| EBITDA | 17 | 0 | -39 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.04 | 5.82 | 5.95 | — | — | — | — | — | — | |
| Gross Margin | 98.76 | 97.65 | 97.58 | — | — | — | — | — | — | |
| Operating Margin | -4.46 | -11.41 | -22.58 | — | — | — | — | — | — | |
| Net Margin | -2.23 | -8.72 | -16.53 | — | — | — | — | — | — | |
| Shares Outstanding | 51 | 50 | 50 | — | — | — | — | — | — | |
| Market Capitalization | 1,632 | 1,736 | 1,475 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D | Feb 18 '26 | Sale | 32.35 | 5,965 | 192,968 | 5,859 | Feb 19 |
| Jallal Bahija | CHIEF EXECUTIVE OFFICER | Feb 18 '26 | Sale | 32.35 | 11,474 | 371,184 | 12,343 | Feb 19 |
| GOLL JOHN | SVP, FINANCE & CAO | Feb 18 '26 | Sale | 32.35 | 698 | 22,580 | 653 | Feb 19 |
| St Leger Tina Amber | CHIEF HR OFFICER | Feb 18 '26 | Sale | 32.35 | 1,000 | 32,350 | 1,119 | Feb 19 |
| Jallal Bahija | CHIEF EXECUTIVE OFFICER | Feb 17 '26 | Option Exercise | 0.00 | 23,817 | 0 | 23,817 | Feb 19 |
| GOLL JOHN | SVP, FINANCE & CAO | Feb 17 '26 | Option Exercise | 0.00 | 1,351 | 0 | 1,351 | Feb 19 |
| Berman David M | HEAD OF R&D | Feb 17 '26 | Option Exercise | 0.00 | 11,824 | 0 | 11,824 | Feb 19 |
| St Leger Tina Amber | CHIEF HR OFFICER | Feb 17 '26 | Option Exercise | 0.00 | 2,119 | 0 | 2,119 | Feb 19 |
| Berman David M | HEAD OF R&D | Dec 05 '25 | Sale | 40.14 | 572 | 22,960 | 0 | Dec 08 |
| Berman David M | HEAD OF R&D | Dec 05 '25 | Option Exercise | 17.46 | 572 | 9,987 | 572 | Dec 08 |
| Berman David M | HEAD OF R&D | Dec 04 '25 | Sale | 40.26 | 31,341 | 1,261,789 | 0 | Dec 08 |
| Berman David M | HEAD OF R&D | Dec 04 '25 | Option Exercise | 17.46 | 31,341 | 547,214 | 31,341 | Dec 08 |
| Berman David M | HEAD OF R&D | Nov 28 '25 | Sale | 40.09 | 5,521 | 221,337 | 0 | Dec 01 |
| Berman David M | HEAD OF R&D | Nov 28 '25 | Option Exercise | 17.46 | 5,521 | 96,397 | 5,521 | Dec 01 |
| Berman David M | HEAD OF R&D | Nov 26 '25 | Sale | 40.12 | 69,404 | 2,784,488 | 0 | Dec 01 |